Several brokerages have updated their recommendations and price targets on shares of Ionis Pharmaceuticals (NASDAQ: IONS) in the last few weeks:

  • 3/10/2017 – Ionis Pharmaceuticals was downgraded by analysts at Goldman Sachs Group Inc from a “neutral” rating to a “sell” rating. They now have a $25.00 price target on the stock, down previously from $28.00.
  • 3/7/2017 – Ionis Pharmaceuticals had its price target lowered by analysts at BMO Capital Markets from $63.00 to $59.00. They now have an “outperform” rating on the stock.
  • 3/6/2017 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $64.00 price target on the stock.
  • 2/28/2017 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $64.00 price target on the stock.
  • 2/27/2017 – Ionis Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. “
  • 2/14/2017 – Ionis Pharmaceuticals had its “positive” rating reaffirmed by analysts at BMO Capital Markets. They now have a $63.00 price target on the stock.
  • 2/13/2017 – Ionis Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $51.00 price target on the stock. According to Zacks, “Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. “

Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) opened at 40.07 on Tuesday. The company’s 50-day moving average is $45.67 and its 200 day moving average is $40.78. Ionis Pharmaceuticals Inc has a 52 week low of $19.59 and a 52 week high of $57.00. The stock’s market capitalization is $4.96 billion.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its earnings results on Tuesday, February 28th. The company reported $0.33 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.45. Ionis Pharmaceuticals had a negative net margin of 77.30% and a negative return on equity of 120.60%. The firm earned $160.30 million during the quarter, compared to the consensus estimate of $97.47 million. During the same period last year, the firm posted ($0.59) EPS. The firm’s revenue for the quarter was up 210.7% on a year-over-year basis. On average, equities analysts forecast that Ionis Pharmaceuticals Inc will post ($0.58) EPS for the current fiscal year.

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/21/analysts-recent-ratings-updates-for-ionis-pharmaceuticals-ions.html

In other Ionis Pharmaceuticals news, SVP C Frank Bennett sold 5,000 shares of the firm’s stock in a transaction dated Friday, March 3rd. The shares were sold at an average price of $55.00, for a total transaction of $275,000.00. Following the completion of the transaction, the senior vice president now directly owns 19,788 shares in the company, valued at approximately $1,088,340. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Stanley T. Crooke sold 15,382 shares of the firm’s stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $46.29, for a total transaction of $712,032.78. Following the transaction, the chief executive officer now owns 30,576 shares of the company’s stock, valued at $1,415,363.04. The disclosure for this sale can be found here. Insiders have sold a total of 73,598 shares of company stock valued at $3,556,863 over the last 90 days. 1.86% of the stock is currently owned by insiders.

Ionis Pharmaceuticals, Inc, formerly Isis Pharmaceuticals, Inc, is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform.

5 Day Chart for NASDAQ:IONS

Receive News & Ratings for Ionis Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.